Belvedere Trading
ORMP icon

Belvedere Trading’s Oramed Pharmaceuticals ORMP Stock Holding History

Belvedere Trading’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,164
Closed -$158K – 1306
2022
Q4 		$158K Sell
13,164
-5,193
-28% -$40.4K ﹤0.01% 386
2022
Q3 		$124K Sell
18,357
-22,333
-55% -$181K ﹤0.01% 179
2022
Q2 		$343K Buy
+40,690
New +$217K 0.01% 121
2021
Q4 		– Sell
-11,972
Closed -$269K – 575
2021
Q3 		$269K Buy
+11,972
New +$204K 0.01% 205

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SIGI
Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Belvedere Trading's ORMP Position: Q1 2023 in Review

Belvedere Trading sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 13,164 shares — an estimated $158K sold.

Belvedere Trading first reported a position in ORMP in Q3 2021 and held it in 4 quarters. The position peaked at $343K in Q2 2022. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

  • Belvedere Trading reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Belvedere Trading sold 13,164 Oramed Pharmaceuticals shares in Q1 2023, an estimated $158K.
  • Belvedere Trading first reported a position in Oramed Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • Belvedere Trading's Oramed Pharmaceuticals position peaked at $343K in Q2 2022.
  • 61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.